Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook

(Updated - November 15, 2016 7:05 AM EST)

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $5.56 billion versus the consensus estimate of $5.75 billion.

The company sees Q3 EPS of $1.34 - $1.44 with revenue of $6.2 - $6.5 billion. The Street sees EPS of $1.42 and revenue of $6.48 billion.

Teva also sees FY16 revenue of $21.6 - $21.9 billion and EPS of $5.10 - $5.20. Consensus estimates call for revenue of $22.1 billion and EPS of $5.16.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Alphabet (GOOG) Tops Q1 EPS by 38c
• World Kinect Corporation (WKC) Misses Q1 EPS by 2c, Misses on Revenue